Booster with strong immune response: Sanofi / GSK want to get back in the rush to corona vaccination

Booster with strong immune response
Sanofi / GSK want to get back into the corona vaccination race

The EU has ordered, but Franco-British cooperation between Sanofi and GlaxoSmithKline has not yet been able to produce an approved corona vaccine. Now a next-generation vaccine should lead the way.

According to the company, a booster vaccination developed by the French group Sanofi together with the British pharmaceutical giant GlaxoSmithKline has shown in clinical studies a “strong immune response” against several variants of the corona virus. These include the omicron variant, which is spreading particularly rapidly, Sanofi explained in Paris.

Sanofì 96.86

Incidentally, according to tests, vaccination would develop 40 times more antibodies against the omicron BA.1 variant than vaccinations based on mRNA technology, Sanofi said in the statement. The French company and GlaxoSmithKline are developing the “next generation” booster vaccine while still awaiting approval for their first generation Corona vaccine. They rely on a protein-based vaccine.

The next-generation vaccine was well tolerated, he said. The full study results will be released in the coming weeks and Sanofi hopes the booster will be approved by the end of the year.

Biontech and Moderna are working on new vaccines

The mRNA technology, on the other hand, is used by Biontech / Pfizer and the US manufacturer Moderna, among others, whose vaccines are already on the world market. These companies are currently working on additional vaccines against the newly emerging variants of the corona virus.

The EU had already signed contracts with Sanofi / GSK to supply hundreds of millions of doses of the vaccine. However, the vaccine has not yet reached market maturity.

About the author


Leave a Comment